{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"}],"units":"Participants"}],"description":"complete and partial hematologic response defined as: Complete response: absence of detectable monoclonal protein in serum and urine, and bone marrow biopsy \\<5% plasma cells with no clonal predominance of kappa or lambda isotype.\n\nPartial response: any one of the following\n\n1. For patients with detectable and quantifiable marrow plasmacytosis, a reduction of 50% or more in plasma cells as a percentage of nucleated bone marrow cells.\n2. For patients with a detectable monoclonal peak on serum protein electropheresis or urine protein electropheresis, a reduction in the peak height of 50% or more.\n3. For patients with quantifiable urinary kappa or lambda chain concentration, a reduction in daily light chain excretion (concentration x 24-hr urine volume).","groups":[{"description":"Mobilization with Filgrastim Stem Cell Collection Bortezomib Melphalan Stem Cell infusion\n\nfilgrastim: 16 mcg/kg daily beginning 3 days before Stem Cell Collectionthrough day before final Stem Cell Collection\n\nbortezomib: 1.0 mg/m2/dose D -6, D-3, D +1, D + 4\n\nmelphalan: 100 mg/m2/dose D -2, D -1\n\nStem Cell Infusion: infusion of previously collected autologous stem cells","id":"OG000","title":"Stem Cell Transplant With Bortezomib and Melphalan"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"one year","title":"Number of Participants With Hematologic Response","type":"PRIMARY","unitOfMeasure":"participants"}